Open Access

High farnesoid X receptor expression predicts favorable clinical outcomes in PD‑L1low/negative non‑small cell lung cancer patients receiving anti‑PD‑1‑based chemo‑immunotherapy

  • Authors:
    • Lina Wang
    • Xiaolong Xu
    • Bin Shang
    • Jian Sun
    • Bin Liang
    • Xingguang Wang
    • Wenjie You
    • Shujuan Jiang
  • View Affiliations

  • Published online on: February 23, 2022     https://doi.org/10.3892/ijo.2022.5330
  • Article Number: 40
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Anti‑programmed death‑1 (PD‑1)/programmed death‑ligand 1 (PD‑L1)‑directed immunotherapy has revolutionized the treatment of advanced non‑small cell lung cancer (NSCLC). However, predictive biomarkers are still lacking, particularly in identifying PD‑L1low/negative patients who will benefit from immunotherapy. It was previously reported that farnesoid X receptor (FXR) downregulated PD‑L1 expression in NSCLC, and that FXRhighPD‑L1low mouse Lewis lung carcinoma tumors showed an increased susceptibility to PD‑1 blockade compared with mock tumors. At present, whether the FXRhighPD‑L1low phenotype predicts clinical response to immunotherapy in patients with NSCLC remains unclear. Herein, a retrospective study was conducted to examine the expression levels of FXR, PD‑L1 and CD8+ T cells by immunohistochemistry in a cohort of 149 patients with NSCLC receiving anti‑PD‑1‑based chemo‑immunotherapy. The results revealed that high FXR and PD‑L1 expression levels were associated with higher objective response rates (ORR) in all patients. High PD‑L1 expression also indicated superior progression‑free survival (PFS). Interestingly, an inverse correlation was identified between FXR and PD‑L1 expression in specimens with NSCLC. Subgroup analysis revealed that high FXR expression was associated with a higher ORR, as well as longer PFS and overall survival (OS) in PD‑L1low patients. Cox multivariate analysis revealed that high FXR expression was an independent predictor for PFS and OS in PD‑L1low patients. Tumor microenvironment evaluation revealed a statistically significant decrease of infiltrating CD8+ T cells in FXRhigh specimens with NSCLC. Overall, the present study proposed an FXRhighPD‑L1low signature as a candidate predictor of response to anti‑PD‑1‑based chemo‑immunotherapy in PD‑L1low/negative patients with NSCLC, providing evidence that could be used to broaden the patients benefitting from immunotherapy.
View Figures
View References

Related Articles

Journal Cover

April-2022
Volume 60 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang L, Xu X, Shang B, Sun J, Liang B, Wang X, You W and Jiang S: High farnesoid X receptor expression predicts favorable clinical outcomes in PD‑L1<sup>low/negative</sup> non‑small cell lung cancer patients receiving anti‑PD‑1‑based chemo‑immunotherapy. Int J Oncol 60: 40, 2022.
APA
Wang, L., Xu, X., Shang, B., Sun, J., Liang, B., Wang, X. ... Jiang, S. (2022). High farnesoid X receptor expression predicts favorable clinical outcomes in PD‑L1<sup>low/negative</sup> non‑small cell lung cancer patients receiving anti‑PD‑1‑based chemo‑immunotherapy. International Journal of Oncology, 60, 40. https://doi.org/10.3892/ijo.2022.5330
MLA
Wang, L., Xu, X., Shang, B., Sun, J., Liang, B., Wang, X., You, W., Jiang, S."High farnesoid X receptor expression predicts favorable clinical outcomes in PD‑L1<sup>low/negative</sup> non‑small cell lung cancer patients receiving anti‑PD‑1‑based chemo‑immunotherapy". International Journal of Oncology 60.4 (2022): 40.
Chicago
Wang, L., Xu, X., Shang, B., Sun, J., Liang, B., Wang, X., You, W., Jiang, S."High farnesoid X receptor expression predicts favorable clinical outcomes in PD‑L1<sup>low/negative</sup> non‑small cell lung cancer patients receiving anti‑PD‑1‑based chemo‑immunotherapy". International Journal of Oncology 60, no. 4 (2022): 40. https://doi.org/10.3892/ijo.2022.5330